This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, D. Articles by Garg, A. Search for Related Content PubMed PubMed Citation Articles by Chen, D. Articles by Garg, A.

Lipodystrophy in Human Immunodeficiency Virus-Infected Patients

Division of Nutrition and Metabolic Diseases, Department of Internal Medicine and the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Address all correspondence and requests for reprints to: Abhimanyu Garg, M.D., University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9052. E-mail: abhimanyu.garg{at}utsouthwestern.edu.

Abstract

Human immunodeficiency virus (HIV) infection is a major global health problem. Recently, combination therapy including HIV-1 protease inhibitors (PIs) has dramatically improved the long-term survival of HIV-infected patients. However, such therapy is associated with a lipodystrophy syndrome characterized by selective loss of sc fat from the face and extremities and, in some patients, accumulation of fat around the neck, dorsocervical region, abdomen, and trunk. Lipodystrophy in HIV-infected patients (LDHIV) is associated with insulin resistance and its metabolic complications such as impaired glucose tolerance, diabetes, hypertriglyceridemia and low serum high density lipoprotein cholesterol levels. PIs appear to be the strongest link to LDHIV; however, fat loss has been reported in some patients taking non-PI antiretroviral drugs. Other factors, such as duration of HIV infection, age, and gender, may also contribute to the risk of development of LDHIV. The molecular basis of LDHIV remains unknown. There is no specific therapy for LDHIV. Avoiding weight gain by reducing energy intake and increasing physical activity may be beneficial in reducing fat accumulation as well as improving metabolic complications. Antihyperglycemic drugs may be used to treat diabetes. Management of dyslipidemia may require lipid-lowering drugs; however, the safety and efficacy of such intervention require further studies. Substitution of PIs with other antiretroviral drugs can mitigate dyslipidemia and glucose intolerance, but whether reversal of lipodystrophy occurs remains unknown. Future research is needed to discover the biochemical and molecular markers of lipodystrophy in HIV patients and develop PIs or other antiretroviral agents that are free of metabolic toxicity.

This article has been cited by other articles:

				J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, and M. Pirmohamed HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options J. Antimicrob. Chemother., October 1, 2008; 62(4): 648 - 660. [Abstract] [Full Text] [PDF]

				L. Mandel and D. Alfi Drug-induced paraparotid fat deposition in patients with HIV: Case reports J Am Dent Assoc, February 1, 2008; 139(2): 152 - 157. [Abstract] [Full Text] [PDF]

				E. Balestreire, J. M. Haught, and J. C. English III Multiple Subcutaneous Lipomas Induced by HAART in the Absence of Protease Inhibitors Arch Dermatol, December 1, 2007; 143(12): 1596 - 1597. [Full Text] [PDF]

				R. A. Hegele, T. R. Joy, S. A. Al-Attar, and B. K. Rutt Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism J. Lipid Res., July 1, 2007; 48(7): 1433 - 1444. [Abstract] [Full Text] [PDF]

				E K. Hester, H. V Chandler, and K. M Sims Fosamprenavir: Drug Development for Adherence Ann. Pharmacother., July 1, 2006; 40(7): 1301 - 1310. [Abstract] [Full Text] [PDF]

				S. B. Haugaard, O. Andersen, S. Madsbad, C. Frosig, J. Iversen, J. O. Nielsen, and J. F.P. Wojtaszewski Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy Diabetes, December 1, 2005; 54(12): 3474 - 3483. [Abstract] [Full Text] [PDF]

				S. B Haugaard, O. Andersen, F. Dela, J. J. Holst, H. Storgaard, M. Fenger, J. Iversen, and S. Madsbad Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic {beta}-cells Eur. J. Endocrinol., January 1, 2005; 152(1): 103 - 112. [Abstract] [Full Text] [PDF]

				U. A. Walker, M. Schott, W. A. Scherbaum, S. R. Bornstein, and A. Garg Acquired and Inherited Lipodystrophies N. Engl. J. Med., July 1, 2004; 351(1): 103 - 104. [Full Text] [PDF]

				A. Garg Acquired and Inherited Lipodystrophies N. Engl. J. Med., March 18, 2004; 350(12): 1220 - 1234. [Full Text] [PDF]

				W. B. Kinlaw and B. Marsh Adiponectin and HIV-Lipodystrophy: Taking HAART Endocrinology, February 1, 2004; 145(2): 484 - 486. [Full Text] [PDF]

				A. Xu, S. Yin, L. Wong, K. Weng Chan, and K. S. L. Lam Adiponectin Ameliorates Dyslipidemia Induced by the Human Immunodeficiency Virus Protease Inhibitor Ritonavir in Mice Endocrinology, February 1, 2004; 145(2): 487 - 494. [Abstract] [Full Text] [PDF]

				C. Fisac, N. Virgili, E. Ferrer, M. J. Barbera, E. Fumero, C. Vilarasau, and D. Podzamczer A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5186 - 5192. [Abstract] [Full Text] [PDF]